Evaluation of single-use tangential flow filtration technology for purification of activated polysaccharides used in conjugate vaccine manufacturing.
TFF
scale up
single use
vaccines
Journal
Biotechnology progress
ISSN: 1520-6033
Titre abrégé: Biotechnol Prog
Pays: United States
ID NLM: 8506292
Informations de publication
Date de publication:
11 2021
11 2021
Historique:
revised:
19
08
2021
received:
07
07
2021
accepted:
24
08
2021
pubmed:
31
8
2021
medline:
26
3
2022
entrez:
30
8
2021
Statut:
ppublish
Résumé
Over the past decade, single-use tangential flow filtration (TFF) technologies have emerged to reduce system preparation time, promote fast and flexible product change over, and ultimately shorten process development and manufacturing time/cost. In this study, the performance of a recently developed Pellicon® single-use TFF capsule was compared against traditional Pellicon® cassettes by assessing TFF process performance (such as flux, residuals clearance, and yield) and post-purification product attributes (such as concentration and mass-weighted average molecular weight). Good scaling was shown by comparing process performance and product attributes across different scales and formats. Additionally, similar TFF process performance and post-purification product attributes were observed for the single-use capsule compared to the reusable TFF cassettes. The capsule requires a smaller flush than the cassette, and it is easier to use since it does not require a compression holder or pre-sanitization. The results provide insight into the application of the single-use TFF capsule and scalability of TFF processes for the purification of conjugate vaccines.
Identifiants
pubmed: 34459567
doi: 10.1002/btpr.3204
pmc: PMC9285785
doi:
Substances chimiques
Polysaccharides
0
Vaccines, Conjugate
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e3204Informations de copyright
© 2021 Pfizer Inc and EMD Millipore Corporation. Biotechnology Progress published by Wiley Periodicals LLC on behalf of American Institute of Chemical Engineers.
Références
Expert Rev Vaccines. 2002 Oct;1(3):399-410
pubmed: 12901578
Biotechnol Prog. 2016 Nov;32(6):1531-1538
pubmed: 27673326
Biotechnol Bioeng. 2019 Mar;116(3):591-597
pubmed: 30450582
Biotechnol Prog. 2021 Nov;37(6):e3204
pubmed: 34459567